Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study

Lancet

Volumn 369, Issue 9571, 2007, Pages 1431-1439

  Mochizuki, Seibu ^a   Dahlöf, Björn ^b   Shimizu, Mitsuyuki ^a   Ikewaki, Katsunori ^a   Yoshikawa, Makoto ^a   Taniguchi, Ikuo ^a   Ohta, Makoto ^a   Yamada, Taku ^a   Ogawa, Kazuhiko ^a   Kanae, Kiyoshi ^a   Kawai, Makoto ^a   Seki, Shingo ^a   Okazaki, Fumiko ^a   Taniguchi, Masayuki ^a   Yoshida, Satoru ^a   Tajima, Naoko ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

VALSARTAN;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; BLOOD PRESSURE REGULATION; CANCER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONJUNCTIVAL HEMORRHAGE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIZZINESS; DRUG DOSE TITRATION; FEMALE; FOLLOW UP; FRACTURE; HEART FAILURE; HEART PALPITATION; HEMOPTYSIS; HERPES ZOSTER; HUMAN; HYPERTENSION; INCIDENCE; ISCHEMIC HEART DISEASE; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; METASTASIS; MORBIDITY; MORTALITY; MULTICENTER STUDY; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; STOMACH DISCOMFORT; STROKE; TRANSIENT ISCHEMIC ATTACK;

EID: 34247379373     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(07)60669-2     Document Type: Article

References (35)

1. Bonow R., Smaha L., Smith Jr. S., Mensah G., and Lenfant C. World Heart Day 2002: the international burden of cardiovascular disease: responding to the emerging global epidemic. Circulation 106 (2002) 1602-1605
2. Kubo M., Kiyohara Y., Kato I., et al. Trends in the incidence, mortality, and survival rate of cardiovascular disease in a Japanese community: the Hisayama study. Stroke 34 (2003) 2349-2354
3. Sadoshima J., and Izumo S. The cellular and molecular response of cardiac myocytes to mechanical stress. Annu Rev Physiol 59 (1997) 551-571
4. Brunner H. Experimental and clinical evidence that angiotensin II is an independent risk factor for cardiovascular disease. Am J Cardiol 87 (2001) 3-9
5. Kim S., and Iwao H. Molecular and cellular mechanisms of angiotensin II mediated cardiovascular and renal diseases. Pharmacol Rev 52 (2000) 11-34
6. Cohn J., Tognoni G., and Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin receptor blocker valsartan in chronic heart failure. N Engl J Med 345 (2001) 1667-1675
7. Pfeffer M., Swedberg K., Granger C., et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 362 (2003) 759-766
8. Pitt B., Poole-Wilson P., Segal R., et al. Effect of losartan compared with captopril on mortality in patients with symptomatic Heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet 355 (2000) 1582-1587
9. Pfeffer M., McMurray J., Velazques E., et al. Valsartan, captopril or both in myocardial infarction complicated by heart failure, left ventricular dysfunction or both. N Engl J Med 349 (2003) 1893-1906
10. Dickstein K., Kjekshus J., and OPTIMAAL Steering Committee. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 360 (2002) 752-760
11. Dahlöf B., Devereux R., Kjeldsen S., et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE) a randomised trial against atenolol. Lancet 359 (2002) 995-1003
12. Schrader J., Luders S., Kulschewski A., et al. Morbidity and mortality after stroke. Eprosartan compared to nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 36 (2005) 1218-1226
13. Viberti F., and Wheelden N. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 106 (2002) 672-678
14. Brenner B., Cooper M., de Zeeuw D., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345 (2001) 861-869
15. Parving H., Lehnert H., Bröchner-Mortensen J., et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345 (2001) 870-878
16. Julius S., Kjeldsen S., Weber M., et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363 (2004) 2022-2031
17. Suzuki K., Souda S., Ikarashi T., et al. Renoprotective effects of low-dose valsartan in type 2 diabetic patients with diabetic nephropathy. Diabetes Res Clin Pract 57 (2002) 179-183
18. Kasama S., Toyama T., Kumakura H., et al. Addition of valsartan to an angiotensin converting enzyme inhibitor improves cardiac sympathetic nerve activity and left ventricular function in patients with congestive heart failure. J Nucl Med 44 (2003) 884-890
19. Munakata M., Nagasaki A., Nunokawa T., et al. Effect of valsartan and nifedipine coat-core on systemic arterial stiffness in hypertensive patients. Am J Hypertens 17 (2004) 1050-1055
20. Kawano H., Toda G., Nakamizo R., Koide Y., Seto S., and Yano K. Valsartan decreases type I collagen synthesis in patients with hypertrophic cardiomyopathy. Circ J 69 (2005) 1244-1248
21. Suzuki H., Kanno Y., and Efficacy of Candesartan on Outcome in Saitama Trial (E-COST) Group. Effects of candesartan on cardiovascular outcomes in Japanese hypertensive patients. Hypertens Res 28 (2005) 307-314
22. Dzau V. The cardiovascular continuum and renin-angiotensin-aldosterone system blockade. J Hypertens 23 suppl 1 (2005) 1-17
23. Mochizuki S., Shimuzu M., Taniguchi I., et al., for the JIKEI HEART Study Group. JIKEI HEART Study - A morbid-mortality and remodeling study with valsartan in Japanese patients with hypertension and cardiovascular disease. Cardiovasc Drugs Ther 18 (2004) 305-309
24. Hansson L., Hedner T., and Dahlöf B. Prospective randomized open blind endpoint (PROBE) study. A novel design for intervention trials. Blood Press 1 (1992) 113-119
25. Pocock S., and Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 31 (1975) 103-115
26. Goldman L., Hashimoto B., Cook E., and Loscalzo A. Comparative reproducibility and validity of systems for assessing cardiovascular functional class: advantages of a new specific activity scale. Circulation 64 (1981) 1227-1234
27. O'Brien P., and Fleming T. A multiple testing procedure for clinical trials. Biometrics 35 (1979) 549-556
28. Munakata M., Nagasaki A., Nunokawa T., et al. Effects of valsartan and nifedipine coat-core on systemic arterial stiffness in hypertensive patients. Am J Hypertens 17 (2004) 1050-1055
29. Yasunari K., Maeda K., Watanabe T., Nakamura M., Yoshikawa J., and Asada A. Comparative effects of valsartan versus amlodipine on left ventricular mass and reactive oxygen species formation by monocytes in hypertensive patients with left ventricular hypertrophy. J Am Coll Cardiol 43 (2004) 2116-2123
30. Saruta T. [The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2004)]. Nippon Rinsho 63 (2005) 952-958
31. Lindholm L., Carlberg B., and Samuelsson O. Should beta-blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 366 (2005) 1545-1553
32. Staessen J., Wang J., and Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J Hypertens 21 (2003) 1055-1076
33. Kimura Y., Takishita S., Muratani H., et al. Demographic study of first-ever stroke and acute myocardial infarction in Okinawa, Japan. Intern Med 37 (1998) 736-745
34. Dzau V., and Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement. Am Heart J 121 (1991) 1244-1263
35. Lewis E., Hunsicker L., Clarke W., et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345 (2001) 851-860